MEDX ... anybody following? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following?

MEDX 31.58

+1.4%

Nov 5 12:44 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	10/15/2007 5:54:39 PM
	of 2240

[From a Reuter's newsstory. Renzo Canetta is referred to as a senior Bristol-Myers research official] But one of Bristol-Myers' most promising experimental cancer drugs, a treatment for melanoma called ipilimumab, is being developed in partnership with Medarex Inc (MEDX.O: Quote, Profile, Research). Bristol aims to seek U.S. approval early next year for use of the drug to treat the dangerous form of skin cancer among patients whose tumors have spread. Instead of directly killing tumors, the drug is designed to coax creation of more T-cells -- immune system soldiers that seek out and attack substances deemed "foreign" to the body. Canetta said tumors shrank among 15 to 20 percent of patients in clinical trials, with about half of those "responders" having a complete disappearance of their melanoma. reuters.com [Renzo M. Canetta, M.D., is vice president of Global Development, Oncology Global Clinical Research. He recently celebrated his 25th anniversary with Bristol-Myers Squibb.]

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next